---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029667"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:01:45.690904+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma reports Q4 net loss $8.0M; cash $127M after $116M raise; CRB-701 shows 43% ORR

## Summary
- Net loss Q4 $8.0M ($1.81/diluted) vs $10.9M ($2.61) YoY; full year loss $44.6M ($10.31).
- Cash, equivalents & investments $127M as of Feb 2, 2024 after $116M capital raise; runway 3+ years through Q1 2027.
- CRB-701 (Nectin-4 ADC) Ph1 data: 43% ORR, 71% DCR at >=2.7 mg/kg; no DLTs, neuropathy, or skin rash. US Ph1 patient dosing starts March 2024.
- FDA cleared IND for CRB-601 (TGFβ blocker); Ph1 start summer 2024. CRB-913 (CB1 inverse agonist) IND filing on track for Q4 2024.
- Appointed Dr. Dominic Smethurst as CMO, previously CMO of Bicycle Therapeutics.

## SEC filing metadata
- accession: 0000950170-24-029667
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/0000950170-24-029667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/crbp-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029667
- JSON: https://secwatch.observer/filing/0000950170-24-029667.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029667.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the fourth quarter of 2023 and year-ended 2023 results: net income the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m, EPS a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $.
  - Period: the fourth quarter of 2023 and year-ended 2023
  - Net income: the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m
  - EPS: a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $
  - Result: reported results
  source text: The Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three months ended December 31, 2023, compared to a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the same period in 2022. For the year ended December 31, 2023, the Company reported a net loss of approximately $44.6 million, or a net loss per diluted share of $10.31, compared to a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15 for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/0000950170-24-029667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.